Drug Profile
Research programme: site specific immunomodulators - Qu Biologics
Alternative Names: SSI - Qu BiologicsLatest Information Update: 25 May 2021
Price :
$50
*
At a glance
- Originator Qu Biologics
- Class Bacterial antigens; Cancer vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Cancer
Most Recent Events
- 20 May 2021 Preclinical trials in Autoimmune disorders in Canada (SC) (Qu Biologics pipeline, May 2021)
- 19 May 2021 Preclinical trials in Cancer in Canada (SC) (Qu Biologics pipeline, May 2021)
- 12 May 2021 Qu Biologics files for patent protection for Site Specific Immunomodulators (SSIs) for the treatment of perioperative immune dysfunction and prevention of cancer metastasis